Departement
Klinische Forschung
Achtung: Diese Seite kann nur von Administratoren besucht werden, da Sie nicht freigeschalten wurde.
Zurück
Publications Papadopoulou Athina

Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance.

Tsagkas C; Parmar K; Pezold S; Barro C; Chakravarty MM; Gaetano L; Naegelin Y; Amann M; Papadopoulou A; Wuerfel J; Kappos L; Kuhle J; Sprenger T; Granziera C; Magon S. Human brain mapping. 2021.

Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study.

Papadopoulou A; Oertel FC; Chien C; Kuchling J; Zimmermann HG; Siebert N; Motamedi S; Souza M; Asseyer S; Bellmann-Strobl J; Ruprecht K; Chakravarty MM; Scheel M; Magon S; Wuerfel J; Paul F; Brandt AU. NeuroImage. Clinical. 2021.

Standardization and digitization of clinical data in multiple sclerosis.

D'Souza M; Papadopoulou A; Girardey C; Kappos L. Nature Reviews Neurology. 2021.

Advances in oral immunomodulating therapies in relapsing multiple sclerosis.

Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L. The Lancet. Neurology. 2020.

Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey.

D'Souza M; Papadopoulou A; Levy M; Jacob A; Yeaman MR; Kümpfel T; Marignier R; Paul F; Brandt AU. Multiple sclerosis and related disorders. 2020.

Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results.

Zuber P; Tsagkas C; Papadopoulou A; Gaetano L; Huerbin M; Geiter E; Altermatt A; Parmar K; Ettlin T; Schuster-Amft C; Suica Z; Alrasheed H; Wuerfel J; Kesselring J; Kappos L; Sprenger T; Magon S. Journal of neurology. 2020.

Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials.

D'Souza M; Heikkilä A; Lorscheider J; Haller V; Kravalis K; Gysin S; Fuertes NAC; Fricker E; Lam E; Higgins P; Tomic D; Papadopoulou A; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.

Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders.

Gkaniatsou T; Papadopoulou A; Paul F; Brandt AU; Oertel FC. ACTA NEUROLOGICA BELGICA. 2020.

Isolated oculomotor palsy due to acute ischemic midbrain stroke.

Kronlage C; Papadopoulou A; De Marchis GM. ACTA NEUROLOGICA BELGICA. 2020.

Longitudinal patterns of cortical thinning in multiple sclerosis.

Tsagkas C; Chakravarty MM; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Magon S. Human brain mapping. 2020.

Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders.

Juenger V; Cooper G; Chien C; Chikermane M; Oertel FC; Zimmermann H; Ruprecht K; Jarius S; Siebert N; Kuchling J; Papadopoulou A; Asseyer S; Bellmann-Strobl J; Paul F; Brandt AU; Scheel M. European Radiology. 2020.

Short timescale modulation of cortical and cerebellar activity in the early phase of motor sequence learning: an fMRI study

Magon S.; Pfister A.; Laura G.; Luthi M.; Papadopoulou A.; Kappos L.; Sprenger T.. Brain Imaging and Behavior. 2020.

Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders.

Asseyer S; Kuchling J; Gaetano L; Komnenić D; Siebert N; Chien C; Scheel M; Oertel FC; Ruprecht K; Bellmann-Strobl J; Finke C; Chakravarty MM; Magon S; Wuerfel J; Paul F; Papadopoulou A; Brandt AU. Multiple sclerosis and related disorders. 2020.

Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.

Magon S; Tsagkas C; Gaetano L; Patel R; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Stippich C; Kappos L; Chakravarty MM; Sprenger T. Journal of neurology. 2020.

Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders.

Papadopoulou A; Oertel FC; Gaetano L; Kuchling J; Zimmermann H; Chien C; Siebert N; Asseyer S; Bellmann-Strobl J; Ruprecht K; Chakravarty MM; Scheel M; Magon S; Wuerfel J; Paul F; Brandt AU. Journal of neurology, neurosurgery, and psychiatry. 2019.

Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.

Papadopoulou A; Gaetano L; Pfister A; Altermatt A; Tsagkas C; Morency F; Brandt AU; Hardmeier M; Chakravarty MM; Descoteaux M; Kappos L; Sprenger T; Magon S. Neurology. 2019.

Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.

Nolan-Kenney RC; Liu M; Akhand O; Calabresi PA; Paul F; Petzold A; Balk L; Brandt AU; Martínez-Lapiscina EH; Saidha S; Villoslada P; Al-Hassan AA; Behbehani R; Frohman EM; Frohman T; Havla J; Hemmer B; Jiang H; Knier B; Korn T; Leocani L; Papadopoulou A; Pisa M; Zimmermann H; Galetta SL; Balcer LJ; International Multiple Sclerosis Visual System Consortium.. Annals of neurology. 2019.

[Optical Coherence Tomography in Disorders of the Central Nervous System].

Papadopoulou A; Oertel FC; Zimmermann H; Zeitz O; Brandt AU; Paul F. Klinische Monatsblatter fur Augenheilkunde. 2018.

Association of clinical headache features with stroke location: An MRI voxel-based symptom lesion mapping study.

Seifert CL; Schönbach EM; Zimmer C; Förschler A; Tölle TR; Feurer R; Gempt J; Papadopoulou A; Magon S; Sprenger T; Poppert H. Cephalalgia : an international journal of headache. 2018.

Cortical Thickness Alterations in Chronic Pain Disorder: An Exploratory MRI Study.

Magon S; Sprenger T; Otti A; Papadopoulou A; Gündel H; Noll-Hussong M. PSYCHOSOMATIC MEDICINE. 2018.

Effects of different endurance exercise modalities on migraine days and cerebrovascular health in episodic migraineurs: A randomized controlled trial.

Hanssen H; Minghetti A; Magon S; Rossmeissl A; Rasenack M; Papadopoulou A; Klenk C; Faude O; Zahner L; Sprenger T; Donath L. SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS. 2018.

Unilateral leg oedema due to spontaneous Achilles tendon rupture.

Papadopoulou A; Kronlage C; Kampmann M; Budweg J. Oxford medical case reports. 2018.

Daclizumab for the treatment of multiple sclerosis.

Papadopoulou A; Derfuss T; Sprenger T. Neurodegenerative disease management. 2017.

Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.

D'Souza M; Yaldizli Ö; John R; Vogt DR; Papadopoulou A; Lucassen E; Menegola M; Andelova M; Dahlke F; Schnyder F; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.

Superior Effects of High-Intensity Interval Training vs. Moderate Continuous Training on Arterial Stiffness in Episodic Migraine: A Randomized Controlled Trial.

Hanssen H; Minghetti A; Magon S; Rossmeissl A; Papadopoulou A; Klenk C; Schmidt-Trucksäss A; Faude O; Zahner L; Sprenger T; Donath L. Frontiers in Physiology. 2017.

Tracking the Evolution of Cerebral Gadolinium-Enhancing Lesions to Persistent T1 Black Holes in Multiple Sclerosis: Validation of a Semiautomated Pipeline.

Andermatt S; Papadopoulou A; Radue EW; Sprenger T; Cattin P. Journal of neuroimaging : official journal of the American Society of Neuroimaging. 2017.

Decision for intravenous thrombolysis in a young patient with acute vertical gaze palsy.

Papadopoulou A; Ahlhelm FJ; Lyrer P; Kuhle J. ACTA NEUROLOGICA BELGICA. 2015.

Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis.

Amann M; Papadopoulou A; Andelova M; Magon S; Mueller-Lenke N; Naegelin Y; Stippich C; Radue EW; Bieri O; Kappos L; Sprenger T. Journal of neurology. 2015.

Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.

Papadopoulou A; Kappos L; Sprenger T. Expert Opinion On Drug Safety. 2015.

Intrathecal gadolinium for magnetic resonance myelography in spontaneous intracranial hypotension: valuable but may be risky--reply.

Papadopoulou A; Ahlhelm FJ; Sprenger T. JAMA Neurology. 2014.

Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis.

Papadopoulou A; Menegola M; Kuhle J; Ramagopalan SV; D'Souza M; Sprenger T; Radue EW; Kappos L; Yaldizli Ö. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.

MRI characteristics of periaqueductal lesions in multiple sclerosis.

Papadopoulou A; Naegelin Y; Weier K; Amann M; Hirsch J; von Felten S; Yaldizli O; Sprenger T; Radue EW; Kappos L; Gass A. Multiple sclerosis and related disorders. 2014.

The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients.

Yaldizli Ö; Penner IK; Frontzek K; Naegelin Y; Amann M; Papadopoulou A; Sprenger T; Kuhle J; Calabrese P; Radü EW; Kappos L; Gass A. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.

Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis

Papadopoulou A.; Muller-Lenke N.; Naegelin Y.; Kalt G.; Bendfeldt K.; Kuster P.; Stoecklin M.; Gass A.; Sprenger T.; Radue E.W.; Kappos L.; Penner I.-K.. Multiple sclerosis (Houndmills, Basingstoke, England). 2013.

Detection of cerebrospinal fluid leaks by intrathecal contrast-enhanced magnetic resonance myelography.

Papadopoulou A; Ahlhelm FJ; Ulmer S; Kappos L; Sprenger T. JAMA Neurology. 2013.

Evolution of MS lesions to black holes under DNA vaccine treatment.

Papadopoulou A; von Felten S; Traud S; Rahman A; Quan J; King R; Garren H; Steinman L; Cutter G; Kappos L; Radue EW. Journal of neurology. 2012.

Teriflunomide for oral therapy in multiple sclerosis.

Papadopoulou A; Kappos L; Sprenger T. Expert Review of Clinical Pharmacology. 2012.

Fatigue and progression of corpus callosum atrophy in multiple sclerosis.

Yaldizli Ö; Glassl S; Sturm D; Papadopoulou A; Gass A; Tettenborn B; Putzki N. Journal of neurology. 2011.

Dimethyl fumarate for multiple sclerosis.

Papadopoulou A; D'Souza M; Kappos L; Yaldizli O. EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2010.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Rudick RA; Lublin FD; Weinstock-Guttman B; Wynn DR; Fisher E; Papadopoulou A; Lynn F; Panzara MA; Sandrock AW; SENTINEL Investigators.. Journal of the neurological sciences. 2010.